Patent to safely combine MDD and IVDD functionality into one unit is granted in Brazil

Report this content

Brighter AB [publ], today announced that Brighter's patent for a safety mechanism when combining injection functionality which is regulated under MDD ("Medical Device Directive") and diagnostic technology which is regulated under IVDD ("In-Vitro Diagnostics Directive") into one unit is being granted in Brazil. The function means that the display of a drug delivery device (e.g. Actiste) is switched off while the user sets the dose, to make the user look at the dose setting and not at the display, which increases patient safety. The patent is an extension of Brighter's main patent and strengthens its protection for combination solutions and the collection of unique treatment data. The patent has already been granted in the US and Europe.

“The International Diabetes Federation estimates almost 17 million adults in Brazil have diabetes. That’s more than 11% of the country’s adult population. This patent is an important step towards bringing the benefits of our diabetes-care solution to Brazil – an important future market for Brighter,” says Christer Trägårdh, interim CEO at Brighter AB.

For further information, please contact:

Investor Relations

Christer Trägårdh, Acting CEO

Certified Adviser

Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10,,

About Brighter AB (publ)

Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.